Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.
about
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapyP2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cellsThe P2Y1 receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is preventedAntiplatelet activity, P2Y₁ and P2Y₁₂ inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'″-P¹ ,P⁴-dithio-P²,P³-chloromethylenetetraphosphateA molecular signaling model of platelet phosphoinositide and calcium regulation during homeostasis and P2Y1 activation.Molecular recognition at purine and pyrimidine nucleotide (P2) receptors.MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in miceA comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif proteinRole of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets.Pharmacochemistry of the platelet purinergic receptors.Reduced expression of P2Y1 receptors in connexin43-null mice alters calcium signaling and migration of neural progenitor cellsCombined blockade of ADP receptors and PI3-kinase p110β fully prevents platelet and leukocyte activation during hypothermic extracorporeal circulationClopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats.A role for nucleotides in support of breast cancer angiogenesis: heterologous receptor signalling.Nucleotide-mediated relaxation in guinea-pig aorta: selective inhibition by MRS2179.Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor.[32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors.Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stressAnti-platelet therapy with clopidogrel prevents endothelial dysfunction and vascular remodeling in aortas from hypertensive rats.Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential.Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist.Anti-platelet therapy: ADP receptor antagonists.Molecular recognition at adenine nucleotide (P2) receptors in platelets.P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions.The impact of commercially available purinergic ligands on purinergic signalling research.The synthesis and initial characterization of an immobilized purinergic receptor (P2Y1) liquid chromatography stationary phase for online screening(N)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets.Novel uses for anti-platelet agents as anti-inflammatory drugs.Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor.Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase.Quantification of recombinant and platelet P2Y(1) receptors utilizing a [(125)I]-labeled high-affinity antagonist 2-iodo-N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([(125)I]MRS2500)Platelet signaling-a primer.P2 receptors and platelet function.Historical perspective on ADP-induced platelet activation.Molecular defects of the platelet P2 receptors.The P2X1 receptor and platelet function.R-Type Ca2+ channels couple to inhibitory neurotransmission to the longitudinal muscle in the guinea-pig ileum.The platelet P2Y(12) receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [(3)H]PSB-0413.Functional interaction between purinergic receptors: effect of ligands for A2A and P2Y12 receptors on P2Y1 receptor function.
P2860
Q24629255-3FCE1FA9-D926-41CD-9CDC-3043EC6A8A88Q26861200-2542BC9C-871A-4BE1-BD64-8CCFD9F45BE9Q28168596-78760704-CCB2-4929-A24B-267E28F1A069Q28537750-7338E6AD-539F-4401-9A76-AEBCFD9169B0Q30484497-96F21A82-45DF-40EA-A282-340C5C00E3D5Q33201399-9FD34F34-2348-4F41-BC91-BDC1F95F823AQ33225547-76148A50-40B6-46F1-88CE-FB5B8E634038Q33267507-BD1C5C27-B477-482C-B919-4C864CF40146Q33495925-C44FA664-9D29-454A-8EAF-CD1A3D5D4723Q33869922-FC2A6B3E-567B-4ACD-8127-D1497528A62BQ34021384-8F385906-1599-4E3D-A248-C60E71751095Q34305447-203088AC-93E9-4450-AECF-5FF2E22DA904Q34705086-500E86C8-7986-494C-9836-06009924DA61Q35006800-A7A86C21-3F9B-4AA5-A489-184349D7B434Q35044028-83BA652D-F207-4A36-A22B-F4C4DF0C0298Q35050462-286C5FD9-6459-41EE-9BAD-1047F5EC2CDEQ35100653-D4D68E2D-7192-444F-883D-2509DB75CC7AQ35100825-B2B3588D-8697-4CAE-91A7-3B430474E52DQ35123162-578BCAC1-C7AD-49DB-BA61-AEDFC12B0276Q35130686-50CDE1BD-917B-41D1-8C92-497E61CA4FE9Q35163180-44EB490E-BDCC-4605-A5B4-D781BDFA214BQ35200801-7FF55966-6B35-48E0-A8C9-5FB12F2F55A9Q35278165-75F2C596-2307-4000-A0FC-071F4C436011Q35580443-72F1C49D-F3A0-4FEB-B90A-92EA0DA8EB54Q35636842-FC4BF604-87DB-45F7-90CB-1405D1DDC3E6Q35693550-76C6D3B5-7692-4EA1-85A3-53179030C8B4Q35910873-E613FB22-2EAF-469B-A069-80CB24B050A6Q36147741-B8DD5DA8-DC4D-4B79-A870-6A10A724BA4EQ36171374-876EF560-5F41-47BD-99C9-D677ECE80CE3Q36316891-730F644F-2634-4419-B9DE-BE0A197196C2Q36610642-A5FA6ECD-751C-468D-8DBE-E8F3879F08ADQ36626943-CFACA066-AEB9-427D-95E1-F61A61C5286EQ37982455-F67F6519-4616-4012-A91F-231108857B27Q38306634-02E40DCF-548C-4C4D-8ED0-ABFD5971C53DQ38306676-C6F0C07D-841D-41CA-A306-0E115871288BQ38306690-A87D1D34-F4AE-425D-81E9-EC7D5855FB92Q38306728-27901598-946F-4DDF-B441-7B2C11EAAB2DQ39069469-1FBEF74D-0E13-439E-851C-7BCF36ABE9DEQ39297464-8333B9D3-4B39-4D0F-8FC5-33369E9AF11FQ39443930-F0EC1DBE-CE5F-4F91-8D85-E365F650D6BA
P2860
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.
@ast
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.
@en
type
label
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.
@ast
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.
@en
prefLabel
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.
@ast
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.
@en
P2093
P1476
Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.
@en
P2093
Bourguignon JJ
Cazenave JP
Raboisson P
P304
P356
10.1016/S0014-2999(01)00733-6
P407
P577
2001-02-01T00:00:00Z